Eric Wang

Eric Wang,

ASO PROF

Department: Molecular Genetics & Microbiology
Business Phone: (352) 273-7601
Business Email: eric.t.wang@ufl.edu

Publications

2021
Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice.
Human molecular genetics. 29(24):3900-3918 [DOI] 10.1093/hmg/ddaa279. [PMID] 33378537.
2021
Transcriptome alterations in myotonic dystrophy frontal cortex.
Cell reports. 34(3) [DOI] 10.1016/j.celrep.2020.108634. [PMID] 33472074.
2020
A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways.
Cell chemical biology. 27(2):223-231.e4 [DOI] 10.1016/j.chembiol.2020.01.003. [PMID] 31981476.
2020
RNA structure probing to characterize RNA-protein interactions on a low abundance pre-mRNA in living cells.
RNA (New York, N.Y.). [DOI] 10.1261/rna.077263.120. [PMID] 33310817.
2020
Sleep disorders in myotonic dystrophies.
Muscle & nerve. 62(3):309-320 [DOI] 10.1002/mus.26866. [PMID] 32212331.
2020
Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer.
Proceedings of the National Academy of Sciences of the United States of America. 117(5):2406-2411 [DOI] 10.1073/pnas.1914286117. [PMID] 31964809.
2020
Structure-Specific Cleavage of an RNA Repeat Expansion with a Dimeric Small Molecule Is Advantageous over Sequence-Specific Recognition by an Oligonucleotide.
ACS chemical biology. 15(2):485-493 [DOI] 10.1021/acschembio.9b00958. [PMID] 31927948.
2020
Transcriptome-wide organization of subcellular microenvironments revealed by ATLAS-Seq.
Nucleic acids research. 48(11):5859-5872 [DOI] 10.1093/nar/gkaa334. [PMID] 32421779.
2019
A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Proceedings of the National Academy of Sciences of the United States of America. 116(42):20991-21000 [DOI] 10.1073/pnas.1901893116. [PMID] 31570586.
2019
Cell-type-specific dysregulation of RNA alternative splicing in short tandem repeat mouse knockin models of myotonic dystrophy.
Genes & development. 33(23-24):1635-1640 [DOI] 10.1101/gad.328963.119. [PMID] 31624084.
2019
Culturing C2C12 myotubes on micromolded gelatin hydrogels accelerates myotube maturation.
Skeletal muscle. 9(1) [DOI] 10.1186/s13395-019-0203-4. [PMID] 31174599.
2019
Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
Proceedings of the National Academy of Sciences of the United States of America. 116(16):7799-7804 [DOI] 10.1073/pnas.1901484116. [PMID] 30926669.
2019
The myotonic dystrophy experience: a North American cross-sectional study.
Muscle & nerve. 59(4):457-464 [DOI] 10.1002/mus.26420. [PMID] 30677147.
2018
An engineered RNA binding protein with improved splicing regulation.
Nucleic acids research. 46(6):3152-3168 [DOI] 10.1093/nar/gkx1304. [PMID] 29309648.
2018
SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F.
The EMBO journal. 37(19) [DOI] 10.15252/embj.201899023. [PMID] 30206144.
2017
A Defective mRNA Cleavage and Polyadenylation Complex Facilitates Expansions of Transcribed (GAA)n Repeats Associated with Friedreich’s Ataxia.
Cell reports. 20(10):2490-2500 [DOI] 10.1016/j.celrep.2017.08.051. [PMID] 28877480.
2017
A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Human molecular genetics. 26(16):3056-3068 [DOI] 10.1093/hmg/ddx190. [PMID] 28535287.
2017
Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.
RNA biology. 14(10):1374-1388 [DOI] 10.1080/15476286.2017.1279787. [PMID] 28102759.
2017
Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics.
Proceedings of the National Academy of Sciences of the United States of America. 114(8):2060-2065 [DOI] 10.1073/pnas.1620874114. [PMID] 28167778.
2017
Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy.
Genes & development. 31(11):1122-1133 [DOI] 10.1101/gad.300590.117. [PMID] 28698297.
2017
Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.
Molecular cell. 68(3):479-490.e5 [DOI] 10.1016/j.molcel.2017.09.033. [PMID] 29056323.
2016
Conservation of context-dependent splicing activity in distant Muscleblind homologs.
Nucleic acids research. 44(17):8352-62 [DOI] 10.1093/nar/gkw735. [PMID] 27557707.
2016
Distal Alternative Last Exons Localize mRNAs to Neural Projections.
Molecular cell. 61(6):821-33 [DOI] 10.1016/j.molcel.2016.01.020. [PMID] 26907613.
2016
Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy.
PLoS genetics. 12(9) [DOI] 10.1371/journal.pgen.1006316. [PMID] 27681373.
2016
Dysregulation of mRNA Localization and Translation in Genetic Disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 36(45):11418-11426 [PMID] 27911744.
View on: PubMed

Grants

Mar 2021 ACTIVE
Evaluation of peptide-oligonucleotide conjugates for myotonic dystrophy
Role: Principal Investigator
Funding: ENTRADA THERAPEUTICS
Jan 2021 ACTIVE
2021 Southeastern Translational Cell Biology Symposium
Role: Other
Funding: CHAN ZUCKERBERG INITIATIVE
Sep 2020 ACTIVE
Identifying and understanding the role of repeat RNAs and RAN proteins in Alzheimer's disease
Role: Other
Funding: NATL INST OF HLTH NIA
Aug 2020 ACTIVE
Development of MRI, Alternative Splicing, and Functional Abilities as Biomarkers in Myotonic Dystrophy Type 1
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAMS
Feb 2020 ACTIVE
Mechanism and function of MBNL mediated mRNA localization in neuronal development and neurologic disease
Role: Principal Investigator
Funding: EMORY UNIV via NATL INST OF HLTH NINDS
Oct 2019 ACTIVE
Distinguished Lectures in Neurodegeneration and Developing Therapies
Role: Other
Funding: SILICON VALLEY COMMUNITY FOU
Sep 2019 ACTIVE
Design and Study of Small Molecules that Cleave the RNA that Causes Myotonic Dystrophy Type 1 (DM1)
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2019 ACTIVE
RNA Processing-Mediated Mechanisms of CNS Dysfunction in Myotonic Dystrophy
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Feb 2019 ACTIVE
Impeding transcription of expanded microsatellite repeats using deactivated Cas9
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Jan 2019 – Dec 2020
Engineering Synthetic RNA Binding Proteins to Probe the Mechanisms of Myotonic Dystrophy and Development of Potential New Therapeutics
Role: Other
Funding: MYOTONIC DYSTROPHY FOU
Dec 2018 ACTIVE
Gridlock in the nervous system altered RNA localization and local translation in neurodegeneration (NDCN ECA)
Role: Principal Investigator
Funding: SILICON VALLEY COMMUNITY FOU
Sep 2018 ACTIVE
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center
Role: Faculty
Funding: UNIV OF ROCHESTER via NATL INST OF HLTH NINDS
Sep 2018 ACTIVE
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center (Project 3 Preclinical Model and Therapies for DM2).
Role: Co-Investigator
Funding: UNIV OF ROCHESTER via NATL INST OF HLTH NINDS
Sep 2018 ACTIVE
Senator Paul D. Wellstone Muscular dystrophy Speciallzed Research Center (Project 2 Disease Progress and Biomarkers)
Role: Co-Investigator
Funding: UNIV OF ROCHESTER via NATL INST OF HLTH NINDS
Aug 2018 ACTIVE
Mechanisms of CNS Dysfunction in Myotonic Dystrophy (MDA578154)
Role: Principal Investigator
Funding: MUSCULAR DYSTROPHY ASSO
May 2018 ACTIVE
Transcriptome studies to enable drug development for repeat expansion diseases
Role: Principal Investigator
Funding: EXPANSION THERAPEUTICS
Feb 2018 – Feb 2020
Therapeutic potential of CRISPR-Cas9 in C9ORF72-repeat deletion strategy in C9ORF72 BAC transgenic mice
Role: Faculty
Funding: CRISPR THERAPEUTICS AG
Sep 2017 ACTIVE
FoxO signaling and skeletal muscle atrophy
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAMS
Aug 2017 ACTIVE
Determining the factors that control dose-dependent splicing regulation by a master regulator
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
Jun 2017 – Nov 2019
OR-DRPD-ROF2017: Advanced microfabricated co-culture devices to study the neuromuscular system
Role: Principal Investigator
Funding: UF DSR OPPORTUNITY FUND
May 2017 – Dec 2020
Therapeutic potential of CRISPR-Cas9 in C9ORF72 ALS/FTD-repeat deletion and transcriptional repression strategies in humanized C9ORF72 BAC transgenic mice
Role: Principal Investigator
Funding: TARGET ALS FOUNDATION via CRISPR THERAPEUTICS AG
Apr 2016 – Mar 2018
PROFILING THE MYOTONIC DYSTROPHY BRAIN TRANSCRIPTOME
Role: Principal Investigator
Funding: UF FOU
Sep 2015 – Aug 2019
Ppst-transcriptional regulation of gene expression in neuromuscular disease
Role: Principal Investigator
Funding: NATL INST OF HLTH OD

Education

PhD
2006-2013 · Harvard-MIT Division of Health Sciences and Technology
BA Biochemistry
2000-2004 · Harvard College

Teaching Profile

Courses Taught
2017-2021
GMS6920 Genetics Journal Colloquy
2019-2021
BMS6003 Genetics and Health
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2017
GMS7794 Neuroscience Seminar
2016
EGN4912 Engineering Directed Independent Research
2021
GMS5905 Special Topics in Biomedical Sciences

Contact Details

Phones:
Business:
(352) 273-7601
Emails: